Co-Existence of CYP2C19*1/*2 and ABCB1c.3435 CT Genotype has a Potential Impact on Clinical Outcome in CAD Patients Treated with Clopidogrel

1 Harnek J, James S, Lagerqvist B. Coronary Artery Perforation and Tamponade ― Incidence, Risk Factors, Predictors and Outcomes From 12 Years’ Data of the SCAAR Registry ―. Circulation Journal. 2020;84(1):43–53. HarnekJ JamesS LagerqvistB Coronary Artery Perforation and Tamponade ― Incidence, Risk Factors, Predictors and Outcomes From 12 Years’ Data of the SCAAR Registry ― Circulation Journal 2020 84 1 43 53 Search in Google Scholar

2 Beitelshees AL, Voora D, Lewis JP. Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med. 2015;8:43–61. BeitelsheesAL VooraD LewisJP Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics Pharmgenomics Pers Med 2015 8 43 61 Search in Google Scholar

3 Siasos G, Oikonomou E, Zaromitidou M, Kioufis S, Kokkou E, Mourouzis K, et al. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy. Atherosclerosis. 2015;242(1):102–8. SiasosG OikonomouE ZaromitidouM KioufisS KokkouE MourouzisK Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy Atherosclerosis 2015 242 1 102 8 Search in Google Scholar

4 Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. New England Journal of Medicine. 2018;379(3):215–25. JohnstonSC EastonJD FarrantM BarsanW ConwitRA ElmJJ Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA New England Journal of Medicine 2018 379 3 215 25 Search in Google Scholar

5 Ellithi M, Baye J, Wilke RA. CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls. Pharmacogenomics. 2020;21(12):889–97. EllithiM BayeJ WilkeRA CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls Pharmacogenomics 2020 21 12 889 97 Search in Google Scholar

6 Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomás M, et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart. 2012;98(2):100–8. ZabalzaM SubiranaI SalaJ Lluis-GanellaC LucasG TomásM Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel Heart 2012 98 2 100 8 Search in Google Scholar

7 Zhu WY, Zhao T, Xiong XY, Li J, Wang L, Zhou Y, et al. Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia. Sci Rep. 2016;6(25478). ZhuWY ZhaoT XiongXY LiJ WangL ZhouY Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia Sci Rep 2016 6 25478 Search in Google Scholar

8 Amin AM, Sheau Chin L, Azri Mohamed Noor D, Sk Abdul Kader MA, Kah Hay Y, Ibrahim B. The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics. Cardiology Research and Practice. 2017;2017:8062796. AminAM Sheau ChinL Azri Mohamed NoorD Sk Abdul KaderMA Kah HayY IbrahimB The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics Cardiology Research and Practice 2017 2017 8062796 Search in Google Scholar

9 Qian W, Chen L, Zhang L, Gao M, Wang C, Qian X, et al. Comparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carrying CYP2C19 loss of function allele. J Thorac Dis. 2022;14(7):2591–601. QianW ChenL ZhangL GaoM WangC QianX Comparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carrying CYP2C19 loss of function allele J Thorac Dis 2022 14 7 2591 601 Search in Google Scholar

10 Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959–67. LeeCR LuzumJA SangkuhlK GammalRS SabatineMS SteinCM Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update Clin Pharmacol Ther 2022 112 5 959 67 Search in Google Scholar

11 Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, et al. Very important pharmacogene summary. Pharmacogenetics and Genomics. 2011;21(3):152–61. HodgesLM MarkovaSM ChinnLW GowJM KroetzDL KleinTE Very important pharmacogene summary Pharmacogenetics and Genomics 2011 21 3 152 61 Search in Google Scholar

12 Su J, Xu J, Li X, Zhang H, Hu J, Fang R, et al. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One. 2012;7(10):9. SuJ XuJ LiX ZhangH HuJ FangR ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis PLoS One 2012 7 10 9 Search in Google Scholar

13 Stokanovic D, Nikolic VN, Konstantinovic SS, Zvezdanovic JB, Lilic J, Apostolovic SR, et al. P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration. Pharmacology. 2015;97(3–4):101–6. StokanovicD NikolicVN KonstantinovicSS ZvezdanovicJB LilicJ ApostolovicSR P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration Pharmacology 2015 97 3–4 101 6 Search in Google Scholar

14 Wang X-q, Shen C-l, Wang B-n, Huang X-h, Hu Z-l, Li J. Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. Gene. 2015;558(2):200–7. WangX-q ShenC-l WangB-n HuangX-h HuZ-l LiJ Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome Gene 2015 558 2 200 7 Search in Google Scholar

15 Hidayat R, Rasyid A, Harris S, Harahap A, Herqutanto, Louisa M, et al. Correlation P2Y12 Genetic Polymorphism As Risk Factor of Clopidogrel Resistance in Indonesian Stroke Patients. Vasc Health Risk Manag. 2023;19:53–61. HidayatR RasyidA HarrisS HarahapA Herqutanto LouisaM Correlation P2Y12 Genetic Polymorphism As Risk Factor of Clopidogrel Resistance in Indonesian Stroke Patients Vasc Health Risk Manag 2023 19 53 61 Search in Google Scholar

16 Su J, Yu Q, Zhu H, Li X, Cui H, Du W, et al. The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population. PLoS One. 2017;12(3). SuJ YuQ ZhuH LiX CuiH DuW The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population PLoS One 2017 12 3 Search in Google Scholar

17 Pan Y, Chen W, Wang Y, Li H, Johnston SC, Simon T, et al. Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial. JAMA Neurol. 2019;76(5):552–60. PanY ChenW WangY LiH JohnstonSC SimonT Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial JAMA Neurol 2019 76 5 552 60 Search in Google Scholar

18 Adamiak-Giera U, Czerkawska A, Olędzki S, Kurzawski M, Safranow K, Jastrzębska M, et al. Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention. Pharmacological Reports. 2021;73(2):583–93. Adamiak-GieraU CzerkawskaA OlędzkiS KurzawskiM SafranowK JastrzębskaM Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention Pharmacological Reports 2021 73 2 583 93 Search in Google Scholar

19 Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, et al. Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease. Jama. 2011;306(20):2221–8. MegaJL HochholzerW FrelingerAL KlukMJ AngiolilloDJ KereiakesDJ Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease Jama 2011 306 20 2221 8 Search in Google Scholar

20 Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–75. SimonT VerstuyftC Mary-KrauseM QuteinehL DrouetE MéneveauN Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 2009 360 4 363 75 Search in Google Scholar

21 Rossini R, Capodanno D, Musumeci G, Lettieri C, Lortkipanidze N, Romano M, et al. Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation. Coron Artery Dis. 2011;22(3):199–205. RossiniR CapodannoD MusumeciG LettieriC LortkipanidzeN RomanoM Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation Coron Artery Dis 2011 22 3 199 205 Search in Google Scholar